Search
Mephenesin
go.drugbank.com/drugs/DB13583ApprovedWithdrawnMephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression . It first entered use in the 1950s.
Carbomycin
go.drugbank.com/drugs/DB11383ExperimentalVet approvedThe structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965. … This antibacterial is obtained from _Streptomyces halstedii_ and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains.
Enuresis
go.drugbank.com/conditions/DBCOND0018540Drugs: ImipramineSynonyms: Enuresis NOS, Enuresis, NOSS-8510
go.drugbank.com/drugs/DB06504ExperimentalIt was being codeveloped by Shionogi and GlaxoSmithKline.
Endostar
go.drugbank.com/drugs/DB11727InvestigationalEndostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Synonyms: Endostatin, N-terminal-MGGSHHHHH, N-TERMINAL-MGGSHHHHH-ENDOSTATINCategories: Non-Fibrillar CollagensNifurizone
go.drugbank.com/drugs/DB19694ExperimentalThe usage of the INN stem 'nifur-' in the name indicates that Nifurizone is a 5-nitrofuran derivative. Nifurizone has a monoisotopic molecular weight of 307.09 Da. … The usage of the INN stem '-zone' in the name indicates that Nifurizone is a anti-inflammatory analgesic, phenylbutazone derivative.
Nifurethazone
go.drugbank.com/drugs/DB20112ExperimentalThe usage of the INN stem 'nifur-' in the name indicates that Nifurethazone is a 5-nitrofuran derivative. Nifurethazone has a monoisotopic molecular weight of 269.11 Da. … The usage of the INN stem '-azone' in the name indicates that Nifurethazone is a anti-inflammatory analgesic, phenylbutazone derivative.
(+)-menthol
go.drugbank.com/drugs/DB11344ApprovedMixtures: Ay Bendito - Pain Relief, Ay Bendito - ThermoactiveINNO-305
go.drugbank.com/drugs/DB06025InvestigationalINNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.
Amrubicin
go.drugbank.com/drugs/DB06263InvestigationalIn 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer